Craft

Certara

Stock Price

$16.2

2024-02-05

Market Capitalization

$2.6 B

2024-02-05

Revenue

$335.6 M

FY, 2022

Certara Summary

Company Summary

Overview
Certara is a biotech company that provides drug discovery and development solutions. Its products include software for pharmacokinetic and pharmacodynamic (PK/PD) analysis; a system for population-based physiological-based modeling and simulation; a tool for preparing clinical trial data for regulatory submission, etc. The company offers consulting, data sciences, medical writing, and document management services. Certara caters to the biopharmaceutical and education sectors.
Type
Public
Status
Active
Founded
2008
HQ
Cranbury, NJ, US | view all locations
Website
https://www.certara.com
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • William F. Feehery

    William F. Feehery, Chief Executive Officer, Director

  • Max Kanevsky

    Max Kanevsky, Chief Technology Officer

  • Leif E. Pedersen

    Leif E. Pedersen, President, Chief Commercial Officer

  • Amin Rostami

    Amin Rostami, Chief Scientific Officer

Operating MetricsView all

Countries (Customers)

70
12.9%

FY, 2022

Enterprise Customers

2.3K
15.0%

FY, 2022

Facility Space Leased, sq. ft.

61K
21.8%

FY, 2022

LocationsView all

21 locations detected

  • Cranbury, NJ HQ

    United States

    100 Overlook Center, Suite 101

  • Ann Arbor, MI

    United States

    6111 Jackson Road

  • Cheltenham, PA

    United States

    165 Township Line Road, Suite 100

  • Durham, NC

    United States

    4505 Emperor Blvd, Suite 220

  • St. Louis, MO

    United States

    222 South Central Avenue, Suite 1008

  • Whitpain, PA

    United States

    1777 Sentry Parkway West, Suite 405

and 15 others

Certara Financials

Summary Financials

Revenue (Q3, 2023)
$85.6M
Gross profit (Q3, 2023)
$49.7M
Net income (Q3, 2023)
($49.0M)
Cash (Q3, 2023)
$272.3M
EBIT (Q3, 2023)
($52.8M)
Enterprise value
$2.6B

Footer menu